共 327 条
[1]
Mellman I(2011)Cancer immunotherapy comes of age Nature. 480 480-9
[2]
Coukos G(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med. 366 2443-54
[3]
Dranoff G(2015)Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies Semin Oncol. 42 495-505
[4]
Topalian SL(2015)PD-1 Blockade in tumors with mismatch-repair deficiency N Engl J Med. 372 2509-20
[5]
Hodi FS(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med. 373 1803-13
[6]
Brahmer JR(2016)Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Lancet. 387 1909-20
[7]
Gettinger SN(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer. 12 252-64
[8]
Smith DC(1992)Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 Cell. 71 1093-102
[9]
McDermott DF(1996)Enhancement of antitumor immunity by CTLA-4 blockade Science. 271 1734-6
[10]
Bracarda S(2005)Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res. 65 1089-96